The OTCQB Venture Market offers early stage and developing companies the benefits of being publicly traded in the US and streamlined market standards which enable listed companies to provide a strong baseline of transparency to inform and engage with US investors.
To be eligible, companies must be current in their reporting, meet a minimum bid price test and undergo an annual verification and management certification process.
As a verified market with efficient access to US investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.
Artelo Biosciences is dedicated to the development and commercialization of proprietary endocannabinoid-modulating therapeutics designed to address significant unmet needs in multiple diseases and conditions, including cancer, pain, and inflammation.
Thermo Fisher Scientific and SHL Medical launch integrated US drug-device manufacturing
Bambusa Therapeutics names new CFO
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004
Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial
Immunic granted European patent for vidofludimus calcium dosing regimens
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Kelun-Biotech and Harbour BioMed receive China IND approval for atopic dermatitis therapy
Melodia Therapeutics reports award of US patent covering MLD-151
GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH